Carriage of serogroup W-135, ET-37 meningococci in The Gambia: Implications for immunisation policy?

被引：37

作者：

MacLennan, JM

Urwin, R

Obaro, S

Griffiths, D

Greenwood, B

Maiden, MCJ ^{[1
]}

机构：

[1] Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England

[2] Univ Oxford, John Radcliffe Hosp, Dept Paediat, Oxford Vaccine Grp, Oxford OX3 9DU, England

[3] MRC Labs, Banjul, Gambia

[4] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England

来源：

LANCET | 2000年 / 356卷 / 9235期

基金：

英国惠康基金;

关键词：

D O I：

10.1016/S0140-6736(00)02734-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We found high levels of symptomless carriage of hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40% of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0%. The recent Hai-associated spread of serogroup W-135, FT-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.

引用

页码：1078 / 1078

页数：1

共 5 条

[1]

*COMM DIS SURV CTR, 2000, COMMUN DIS REP CDR W, V10, P129

[2]

*COMM DIS SURV CTR, 2000, COMMON DIS REP CDR W, V10, P133

[3] Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa [J].

Kwara, A ;

Adegbola, RA ;

Corrah, PT ;

Weber, M ;

Achtman, M ;

Morelli, G ;

Caugant, DA ;

Greenwood, BM .

TROPICAL MEDICINE & INTERNATIONAL HEALTH, 1998, 3 (09) :742-746

[4]

Maiden MCJ, 1999, LANCET, V354, P615, DOI 10.1016/S0140-6736(99)00252-4

[5]

MOORE PS, 1989, LANCET, V2, P260

← 1 →